NCT06856681View on ClinicalTrials.gov

Clinical Utility of Early Vs. Late Blood Biomarker Testing for Alzheimer's Disease

NANot yet recruitingINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

March 31, 2028

Conditions
Alzheimers Disease
Interventions
DIAGNOSTIC_TEST

PrecivityAD2 - Early Testing

Participants in Cohort A will receive PrecivityAD2 testing at Visit 1, with results disclosed shortly after testing.

DIAGNOSTIC_TEST

PrecivityAD2 - Delayed Testing

Participants in Cohort B will receive PrecivityAD2 testing at Visit 2, with results disclosed shortly after testing.

Sponsors

Lead Sponsor

C2N Diagnostics
All Listed Sponsors
collaborator

Alzheimer's Association

OTHER

lead

C2N Diagnostics

INDUSTRY

NCT06856681 - Clinical Utility of Early Vs. Late Blood Biomarker Testing for Alzheimer's Disease | Biotech Hunter | Biotech Hunter